Phase II Randomized Trial of BI 730357, a Novel Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis

By sjmartinez • January 24, 2025

Gooderham MJ, Mrowietz U, Kadus W, Drda K, Gu H, Vangerow H, Flack M, Korell J, Sofen H, Papp KA. Phase II Randomized Trial of BI 730357, a Novel Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis. J Invest Dermatol. 2025 Jan 21:S0022-202X(25)00034-X. doi: 10.1016/j.jid.2024.12.025. Epub ahead of print. PMID: 39848568.

Tags: clinical trials, Cytokines, Dermatology, Inflammatory skin diseases, Olive View DoM, psoriasis, Publications

Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials

Armstrong AW, Lebwohl M, Warren RB, Sofen H, Morita A, Paul C, Papp KA, Colombo MJ, Scotto J, Vaile J, Zhuo J, Vritzali E, Berger[...]

Ethical Considerations in Recommending Patients Avoid Cosmetic Treatments Performed by Non-Physician Providers

Hill RC, Grant-Kels JM, Farshchian M. Ethical Considerations in Recommending Patients Avoid Cosmetic Treatments Performed by Non-Physician Providers. J Am Acad Dermatol. 2025 Feb 24:S0190-9622(25)00356-1.[...]

Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With Psoriasis

Armstrong AW, Lee K, Yee D, Woodbury M, Zundell M, Zagona-Prizio C, Yousif J, Grant C, Shields A, Chou P, Callis Duffin K, Gottlieb AB,[...]